Kolon Life Science Inc.

A102940

KR7102940004

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
22,050 ^KRW	-3.50%		-0.68%	-14.20%

Mar. 20	Kolon Life Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 05	Kolon Biotech, Inc. announced that it has received KRW 2.001 billion in funding from Kolon Life Science Inc.	CI

Kolon Life Science Inc.(KOSDAQ:A102940) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Kolon Life Science Inc.

Kolon Life Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Kolon Biotech, Inc. announced that it has received KRW 2.001 billion in funding from Kolon Life Science Inc.	Mar. 04	CI
Kolon Biotech, Inc. announced that it expects to receive KRW 2.0068 billion in funding from Kolon Life Science Inc.	Jan. 16	CI
Kolon Life Science Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Kolon Life Science Inc.(KOSDAQ:A102940) added to S&P Global BMI Index	23-09-18	CI
Kolon Life Science Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Kolon Biotech, Inc. announced that it has received KRW 5.112 billion in funding from Kolon Life Science Inc.	23-07-20	CI
Kolon Biotech, Inc. announced that it expects to receive KRW 5.112 billion in funding from Kolon Life Science Inc.	23-07-11	CI
Kolon Life Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Kolon Biotech, Inc. announced that it expects to receive KRW 994 million in funding from Kolon Life Science Inc.	23-05-08	CI
Kolon Biotech, Inc. announced that it expects to receive KRW 1.5 billion in funding from Kolon Life Science Inc.	23-04-10	CI
Kolon Biotech, Inc. announced that it expects to receive KRW 1.005 billion in funding from Kolon Life Science Inc.	23-03-27	CI
Kolon Life Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
Kolon Biotech, Inc. announced that it expects to receive KRW 2.511 billion in funding from Kolon Life Science Inc.	23-01-18	CI
Kolon Life Science Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Kolon Biotech, Inc. announced that it expects to receive KRW 2.499 billion in funding from Kolon Life Science Inc.	22-10-17	CI
Kolon Life Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Kolon Biotech, Inc. announced that it has received KRW 5.562 billion in funding from Kolon Life Science Inc.	22-04-25	CI
Kolon Biotech, Inc. announced that it expects to receive KRW 5.562 billion in funding from Kolon Life Science Inc.	22-04-24	CI
Kolon Biotech, Inc. announced that it has received KRW 5.06 billion in funding from Kolon Life Science Inc.	22-04-18	CI
Kolon Life Science Enters $600 Million Deal to License out Gene Therapy Drug to Singapore's Juniper Biologics	22-04-14	MT
Juniper Biologics Pte Ltd Acquires Cell-Mediated Gene Therapy TG-C LD for Treatment of Knee Osteoarthritis	22-04-12	CI
Kolon Life Science Inc.(KOSDAQ:A102940) dropped from S&P Global BMI Index	22-03-21	CI
Kolon Life Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-16	CI
Kolon Life Science Inc. announced that it has received KRW 40 billion in funding	21-12-09	CI

KOLON LIFE SCIENCE Inc. is a Korea-based company mainly engaged in the manufacturing of functional materials. The Company operates its business under two segments. The Chemical Business segment produces and sells raw drug products, which are the raw materials of new drugs and generic drugs, antibacterial agents that suppress bacterial growth, water treatment agents for environmental purification, and functional material products for cosmetics. The Bio Business segment manufactures and sells bio new medicines based on cell gene therapy products.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KOLON LIFE SCIENCE INC.	-14.20%	183M
ELI LILLY AND COMPANY	+25.56%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.58%	352B
MERCK & CO., INC.	+19.98%	332B
ABBVIE INC.	+3.02%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-5.19%	145B